Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma.
High dose chemoradiotherapy and haematopoietic stem cell transplantation (SCT) is used as primary therapy for patients diagnosed with Burkitt lymphoma (BL). Forty-three adults presented with sporadic BL in British Columbia between 1987 and 2003. Twenty patients had bone marrow involvement. Sixteen patients did not proceed to SCT because of chemorefractory disease (n = 9) or other reasons (n = 7). Twenty-seven patients proceeded to SCT and had a 3-year event-free survival of 51%. In conclusion, approximately 50% of patients with chemosensitive BL who undergo SCT can be cured; however, a significant number of patients will not proceed to SCT because of early resistance or recurrence.
Song
Kevin W
KW
Division of Hematology, Leukemia/Bone Marrow Transplant Program of British Columbia, the Vancouver Hospital and Heath Science Centre, Vancouver, BC, Canada. ksong@bccancer.bc.ca
Barnett
Michael J
MJ
Gascoyne
Randy D
RD
Horsman
Douglas E
DE
Forrest
Donna L
DL
Hogge
Donna E
DE
Lavoie
Julyle C
JC
Nantel
Stephen H
SH
Nevill
Thomas J
TJ
Shepherd
John D
JD
Smith
Clayton A
CA
Sutherland
Heather J
HJ
Voss
Nicholas J
NJ
Toze
Cynthia L
CL
Connors
Joseph M
JM
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002051:Burkitt Lymphoma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome